Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7660116 | 0.73 | NOTUM (0.36) | NPC1RAB9A | |
| SCHEMBL31373399 | 0.72 | RECQL (0.42) | NPC1 | |
| SCHEMBL8567935 | 0.71 | ALDH1A1 (0.40) | RAB9A | |
| SCHEMBL18299679 | 0.69 | LMNA (0.43) | — | |
| SCHEMBL15771678 | 0.68 | CA2 (0.43) | NPC1RAB9A | |
| SCHEMBL8568386 | 0.68 | CSNK2A1 (0.38) | — | |
| SCHEMBL6961763 | 0.68 | TDP1 (0.49) | — | |
| SCHEMBL7668274 | 0.67 | ALDH1A1 (0.44) | NPC1RAB9A | |
| SCHEMBL18795550 | 0.67 | — | — | |
| SCHEMBL6152929 | 0.67 | CTSB (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6344462-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| US-6100284-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-6008229-A | TREATING ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0861243-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |